Role / Responsibilities
Jounce Therapeutics is seeking an experienced translational immunologist to join the TranslationalExploratory and Clinical Immunology team and contribute to the development of novel cancerimmunotherapies. The successful candidate will be responsible for managing multiple aspects ofbiomarker assays in on-going clinical trials. They will be applying Flow Cytometry and otherimmunoassays to develop and execute on a predicative and pharmacodynamic biomarker strategy. Aspart of a multi-disciplinary team, they will be expected to proactively interact with project teams, externalcollaborators and drive lab-based research to bring best-in-class biomarker strategies to Jounce clinicalprograms.
Contribute scientific leadership to Jounce clinical programs, representing function within largerprogram team for vopratelimab development.
Gain subject matter expertise for on-going clinical biomarker assays for vopratelimabdevelopment in the SELECT trial and beyond.
Work cross-functionally within Research to identify and establish assays and technologies tosupport mechanistic studies and biomarker validation.
Manage and guide the development of SOPs for the central lab; manage the scientific review, QCand presentation of external vendor results.
Contribute to scientific rationale for combination strategy for Jounce pipeline programs.
Train and continuously develop scientists and associates in the Translational ExploratoryImmunology group.
Ph.D., M.D. or DVM in Immunology or related field with a minimum of 3 years' experiencerequired, (industrial experience preferred); or MS candidates with a minimum of 10 years'research experience in industry setting and strong scientific background.
In-depth knowledge and hands-on experience with Flow Cytometry procedures and demonstratedability to mentor and train junior associates.
Hands-on experience with T cell agonists, co-stimulatory molecules and/or ICOS is a plus.
Experience with the design, development and analysis of cellular, protein-based, and/ormolecular assays.
Good understanding of clinical drug development strategies.
Familiarity with coordinating third party outsourced assays, standards, interpretation, andreporting.
Experience in immuno-oncology, biologics, molecular biology and cell biology preferred.
Demonstrated excellent interpersonal, verbal and written communication skills.
Excel in cross-functional, collaborative and fast-paced settings.
Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employmentdecisions on the basis of race, color, national origin, age, physical or mental disability, marital status,religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicantsshould be legally entitled to work for any employer in the U.S.To apply, please visit https://careers-jouncetx.icims.com/.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumorassociated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.